Eisai Obtains Rights To Overactive Bladder Agent Uritos In 13 Asian Countries

Japanese drug maker Kyorin Pharmaceutical signed a licensing agreement with Eisai Sept. 29 giving Eisai exclusive rights to develop and market overactive bladder agent Uritos (imidafenacin) in China, India, Sri Lanka and 10 ASEAN countries